Brad Stanfield: The 60-Year Cholesterol War Is Finally Over

Key Takeaways

• Target LDL below 55 mg/dL for optimal cardiovascular protection, not just the standard 70 mg/dL.
• Consider PCSK9 inhibitors (evolocumab) if you have high-risk conditions like diabetes or atherosclerosis, even without prior heart events.
• Use statins + ezetimibe as a cost-effective alternative to achieve aggressive LDL targets if PCSK9 inhibitors are inaccessible.
• Don’t wait for symptoms to treat high LDL—early intervention prevents heart attacks and strokes.
• Monitor LDL annually even if levels appear “normal” (e.g., 67 mg/dL), as plaque can still develop.

Notable Quotes

“I think this study changes the paradigm. We don’t have to wait until someone has atherosclerosis to treat them intensively.” — Dr. Nicholas Marston

Bottom Line

Aim for LDL cholesterol below 55 mg/dL using available therapies (statins, ezetimibe, or PCSK9 inhibitors) to significantly reduce heart disease risk, especially if you’re high-risk—don’t wait for symptoms to act.

Watch the Full Video